Targeted protein degradation presents a promising strategy to address antimicrobial resistance, focusing on innovative ...

Proteasomes are molecular machines for breaking down proteins. Drugmakers are working to coopt this process with targeted therapies. This story was originally published on BioPharma Dive. To receive ...

A new active substance attacks a key protein in tumor cells, leading to complete degradation. In cell experiments, this caused cancer cells to lose their protection and die. The active substance was ...

Targeted protein degradation has moved well beyond its prologue more than 20 years ago. 1 The number of publications describing different PROTACs (PROteolysis TArgeting Chimeras), molecular glues, and ...

Targeted protein degradation (TPD) is transforming drug discovery by leveraging the cell’s natural protein disposal systems to eliminate disease-causing proteins. Innovators are making rapid and ...

"Dosing the first patient in our Phase 1/2 trial of NEO-811 in renal cell carcinoma marks a pivotal inflection point for Neomorph, representing the first clinical evaluation of an asset from our ...

Ascentage Pharma will be conducting a multicenter, open-label Phase I study designed to evaluate the safety, tolerability, ...

Researchers have developed smart nanoparticles that can seek out and destroy disease-causing proteins the body can’t normally eliminate. Unlike traditional drugs, these particles can reach ...

Researchers developed nanotechnology that selectively binds and degrades abnormal proteins. The technology shows promise for ...

The company joins a group of degrader ADC (or DAC) developers that includes Bristol Myers Squibb and Pfizer.